these offices received OCI and FDA specific training tailored expressly toward FDA's many areas of responsibility using the facilities located at the Federal Law Enforcement Training Center (FLETC). While the agents were attending training at FLETC, OCI was required to become operational in response to reports that several consumers across the nation were claiming they had found syringes in Diet Pepsi products. OCI deployed agents from the FLETC training course to lead the investigation of this nationwide tampering scare. The United States Attorney's offices recognized the serious ramifications of people making false tampering reports and provided their support for the OCI investigation. The resulting outcome of the investigation and the arrests of those making false tampering claims put a stop to the rash of tampering reports. In the end, over 60 individuals were successfully prosecuted for violation of the FATA. Opening of offices In the summer of 1993, OCI opened three more offices in Chicago, New York and Metropolitan Washington, D.C. Since opening six field offices in 1993, six resident offices and 26 domicile offices have become operational throughout the United States and Puerto Rico. Regulation The FDA regulates approximately 25 cents of every dollar spent annually by American consumers. FDA is responsible for regulating products to ensure the safety of foods, prescription and over-the-counter drugs, biological products such as vaccines and blood, medical devices, cosmetics, radiation-emitting products, and more. Misconduct allegations The agency has come under scrutiny on multiple occasions. In 2010, director Terry Vermillion stepped down after allegations surfaced that he had abused his power. In 2016, the agency was subject to scrutiny once again after Reuters news agency reported in a series of articles that the agency, under its new director George Karavetsos, had been potentially wasting resources by pursuing cases that lacked prosecutorial merit, often targeting legitimate drugs labelled for foreign countries and claiming that they were mislabelled. According to Reuters, critics have argued that many of these cases posed little threat to public health and that many cases failed to show any clear signs of criminal intention on the part of the alleged perpetrators. Furthermore, evidence surfaced of agents acting in a threatening and aggressive manner. Shortly after Reuters published these articles, the House Committee on Energy and Commerce launched a review of the agency. The following January, under circumstances reminiscent of Vermillion's resignation in 2010, Karavetsos stepped down, not disclosing his reasons for doing